0001415889-24-002957.txt : 20240207
0001415889-24-002957.hdr.sgml : 20240207
20240207180011
ACCESSION NUMBER: 0001415889-24-002957
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240205
FILED AS OF DATE: 20240207
DATE AS OF CHANGE: 20240207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NIVEN RALPH
CENTRAL INDEX KEY: 0001168060
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24606145
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-02072024_060201.xml
X0508
4
2024-02-05
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001168060
NIVEN RALPH
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
CHIEF SCIENTIFIC OFFICER
1
Common Stock
2024-02-05
4
M
0
1400
1.74
A
3009
D
Common Stock
2024-02-05
4
M
0
3200
2.14
A
6209
D
Common Stock
2024-02-05
4
S
0
4600
17.4455
D
1609
D
Stock Option (Right to Buy)
1.74
2024-02-05
4
M
0
900
0
D
2030-09-03
Common Stock
900
13308
D
Stock Option (Right to Buy)
1.74
2024-02-05
4
M
0
500
0
D
2030-09-03
Common Stock
500
9088
D
Stock Option (Right to Buy)
2.14
2024-02-05
4
M
0
500
0
D
2031-04-01
Common Stock
500
10894
D
Stock Option (Right to Buy)
2.14
2024-02-05
4
M
0
1200
0
D
2031-04-01
Common Stock
1200
34908
D
Stock Option (Right to Buy)
2.14
2024-02-05
4
M
0
1500
0
D
2031-04-01
Common Stock
1500
41732
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
/s/ George A. Eldridge, Attorney-in-Fact
2024-02-07